Atea Pharmaceuticals (AVIR) Projected to Post Quarterly Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR) will likely be releasing its earnings data after the market closes on Thursday, March 6th. Analysts expect Atea Pharmaceuticals to post earnings of ($0.35) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Atea Pharmaceuticals Price Performance

Shares of AVIR stock opened at $2.90 on Wednesday. Atea Pharmaceuticals has a 52 week low of $2.75 and a 52 week high of $4.18. The stock has a market capitalization of $244.94 million, a PE ratio of -1.40 and a beta of 0.19. The firm has a 50 day moving average of $3.17 and a two-hundred day moving average of $3.36.

Insider Buying and Selling at Atea Pharmaceuticals

In other Atea Pharmaceuticals news, Director Franklin M. Berger sold 359,606 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total value of $1,024,877.10. Following the completion of the transaction, the director now owns 451,897 shares of the company’s stock, valued at $1,287,906.45. This trade represents a 44.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 17.80% of the stock is currently owned by corporate insiders.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.